[
    [
        {
            "time": "2018-01-01",
            "original_text": "医药生物行业周报：近我国医药产业创新环境的变化",
            "features": {
                "keywords": [
                    "医药",
                    "生物",
                    "创新",
                    "环境"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药生物行业周报：近我国医药产业创新环境的变化",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "医药行业周报：政策逐步落地实施聚焦创新和产业升级",
            "features": {
                "keywords": [
                    "医药",
                    "政策",
                    "创新",
                    "产业升级"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药行业周报：政策逐步落地实施聚焦创新和产业升级",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-03",
            "original_text": "医疗保健：同时明确首家生物类似药为高荐14股",
            "features": {
                "keywords": [
                    "医疗",
                    "保健",
                    "生物",
                    "类似药",
                    "荐股"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "保健"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医疗保健：同时明确首家生物类似药为高荐14股",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-04",
            "original_text": "医药行业2018年投资策略：正本清源柳暗花明",
            "features": {
                "keywords": [
                    "医药",
                    "投资策略",
                    "正本清源"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业2018年投资策略：正本清源柳暗花明",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-05",
            "original_text": "医药生物行业周报:新年新环境，政策新红利",
            "features": {
                "keywords": [
                    "医药",
                    "生物",
                    "新年",
                    "政策",
                    "红利"
                ],
                "sentiment_score": 0.85,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药生物行业周报:新年新环境，政策新红利",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-06",
            "original_text": "医疗保健行业热点速评：首批通过一致性评价品种诞生开启仿制药去产能周期",
            "features": {
                "keywords": [
                    "医疗",
                    "保健",
                    "一致性评价",
                    "仿制药",
                    "去产能"
                ],
                "sentiment_score": 0.65,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗",
                    "保健"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医疗保健行业热点速评：首批通过一致性评价品种诞生开启仿制药去产能周期",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-07",
            "original_text": "医药行业2018年策略报告:把握政策主线,关注结构性机会",
            "features": {
                "keywords": [
                    "医药",
                    "政策",
                    "结构性机会"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业2018年策略报告:把握政策主线,关注结构性机会",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-08",
            "original_text": "【医药】江琦：医药生物行业2018年1月月报：2018是政策落地大年，看好创新药、高品质仿制药、医疗服务三大方向-增持-0101",
            "features": {
                "keywords": [
                    "医药",
                    "生物",
                    "政策",
                    "创新药",
                    "仿制药",
                    "医疗服务",
                    "增持"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【医药】江琦：医药生物行业2018年1月月报：2018是政策落地大年，看好创新药、高品质仿制药、医疗服务三大方向-增持-0101",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]